Cargando…

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy

Clinical progressive disease (cPD) occurs during neoadjuvant chemotherapy (NAC) in 3%–5% of triple‐negative breast cancer (TNBC) patients. We aimed to identify the histopathological and immunohistochemical parameters that are correlated with the TNBC that showed cPD. We identified 22 TNBCs that show...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanabe, Yuko, Tsuda, Hitoshi, Yoshida, Masayuki, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Yamamoto, Seiichiro, Kinoshita, Takayuki, Fujiwara, Yasuhiro, Tamura, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497804/ https://www.ncbi.nlm.nih.gov/pubmed/28474753 http://dx.doi.org/10.1111/cas.13274

Ejemplares similares

Primary Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
por: Harano, Kenichi, et al.
Publicado: (2012)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles
por: Sawada, Takeshi, et al.
Publicado: (2018)

Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012)

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

TERT promoter hotspot mutations in breast cancer
por: Shimoi, Tatsunori, et al.
Publicado: (2017)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Use of Cox's Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
por: Asano, Junichi, et al.
Publicado: (2013)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
por: Tamura, Kenji, et al.
Publicado: (2018)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Immunohistochemical Profile for Unknown Primary Adenocarcinoma
por: Hashimoto, Kenji, et al.
Publicado: (2012)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Ryu, Shoraku, et al.
Publicado: (2020)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Drug induced interstitial lung disease in oncology phase I trials
por: Yonemori, Kan, et al.
Publicado: (2016)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ
por: Tamura, Nobuko, et al.
Publicado: (2015)

Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma
por: Sugano, Teppei, et al.
Publicado: (2020)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
por: Hirata, T, et al.
Publicado: (2009)

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017)

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials
por: Tanabe, Yuko, et al.
Publicado: (2016)

Nucleostemin expression in invasive breast cancer
por: Kobayashi, Takayuki, et al.
Publicado: (2014)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Locally advanced triple negative breast cancer arising from fibroadenoma with complete response to neoadjuvant chemotherapy: A case report
por: Shiino, Sho, et al.
Publicado: (2020)

Novel combination of serum microRNA for detecting breast cancer in the early stage
por: Shimomura, Akihiko, et al.
Publicado: (2016)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy
por: Sekine, Chikako, et al.
Publicado: (2022)

Baseline risk of recurrence in stage I–II endometrial carcinoma
por: Sasada, Shinsuke, et al.
Publicado: (2018)

A novel prediction score for predicting the baseline risk of recurrence of stage I–II endometrial carcinoma
por: Takahashi, Kenta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l5l04e84n1eutqt8t1q84m8p6s